Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Change in Cash (2017 - 2025)

VYNE Therapeutics' Change in Cash history spans 9 years, with the latest figure at -$6.2 million for Q2 2025.

  • For Q2 2025, Change in Cash fell 158.49% year-over-year to -$6.2 million; the TTM value through Jun 2025 reached -$7.6 million, down 184.97%, while the annual FY2025 figure was $4.1 million, 138.16% up from the prior year.
  • Change in Cash reached -$6.2 million in Q2 2025 per VYNE's latest filing, down from $8.3 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $61.0 million in Q1 2021 to a low of -$51.1 million in Q3 2021.
  • Average Change in Cash over 5 years is -$2.0 million, with a median of -$5.7 million recorded in 2023.
  • Peak YoY movement for Change in Cash: skyrocketed 429.68% in 2023, then plummeted 1562.59% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$10.1 million in 2021, then soared by 54.24% to -$4.6 million in 2022, then surged by 429.68% to $15.2 million in 2023, then tumbled by 76.23% to $3.6 million in 2024, then tumbled by 270.83% to -$6.2 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Change in Cash are -$6.2 million (Q2 2025), $8.3 million (Q1 2025), and $3.6 million (Q4 2024).